Prevalence of AmpC beta-lactamase producing Escherichia coli and Klebsiella pneumoniae in Africa: a systematic review and meta-analysis.

IF 4.4 2区 医学 Q1 INFECTIOUS DISEASES
Saba Gebremichael Tekele, Zewudu Mulatie, Alemu Gedefie, Hussen Ebrahim, Brukitawit Eshetu, Mihret Tilahun, Habtu Debash, Agumas Shibabew, Ousman Mohammed, Ermiyas Alemayehu, Daniel Gebretsadik Weldehanna, Melaku Ashagrie Belete
{"title":"Prevalence of AmpC beta-lactamase producing Escherichia coli and Klebsiella pneumoniae in Africa: a systematic review and meta-analysis.","authors":"Saba Gebremichael Tekele, Zewudu Mulatie, Alemu Gedefie, Hussen Ebrahim, Brukitawit Eshetu, Mihret Tilahun, Habtu Debash, Agumas Shibabew, Ousman Mohammed, Ermiyas Alemayehu, Daniel Gebretsadik Weldehanna, Melaku Ashagrie Belete","doi":"10.1186/s13756-025-01578-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The emergence of AmpC beta-lactamase (AmpC) poses a significant challenge in the context of antimicrobial resistance (AMR). AmpC confers resistance to narrow- and broad- spectrum cephalosporins, beta-lactam/beta-lactamase inhibitor combinations and aztreonam making it clinically relevant and presenting a formidable threat to effective therapeutic interventions. Thus, the aim of this study was to assess magnitude of AmpC producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) in Africa.</p><p><strong>Methods: </strong>Articles were extensively searched in bibliographic databases and grey literature using entry terms and combinations key words. Electronic databases such as PubMed, Scopus, Science Direct, Embase, and other online sources such as African Journal Online, Google Scholar, and ResearchGate were used to find relevant articles. Furthermore, the Joanna Briggs Institute quality appraisal tool was used to assess the quality of the included studies. Studies meeting eligibility criteria were extracted in MS Excel and exported to STATA version 14 software for statistical analysis. A random-effects model was used to compute the pooled prevalence of AmpC producing E. coli and K. pneumoniae. Heterogeneity was quantified by using the Cochrane Q test and I<sup>2</sup> statistics. Publication bias was assessed using a funnel plot and Egger's test. Additionally, sensitivity analysis was conducted to assess the impact of a single study on the pooled effect size.</p><p><strong>Result: </strong>Of the 2,619 studies identified, 25 studies were eligible for quantitative analysis, involving a total of 11,908 E. coli, and 4,654 K. pneumoniae isolates. The overall pooled prevalence of AmpC producing E. coli and K. pneumoniae in Africa was 18.79% (95% CI: 15.00, 22.58). The pooled prevalence of AmpC producing E. coli and K. pneumoniae were 15.32% (95% CI: 12.03, 18.61) and 17.25% (95% CI: 13.18, 21.32), respectively. There was significant heterogeneity among studies (I<sup>2</sup> = 99.0%, p < 0.001). Our study depicted that Egypt had the highest pooled prevalence of AmpC producing E. coli and K. pneumoniae with 28.91% (14.74, 43.08) and 27.84% (8.47, 47.21) respectively. Furthermore, studies conducted after 2020 showed the highest pooled prevalence of AmpC producing E. coli 28.29% (11.78, 44.80) and K. pneumoniae 29.04% (13.13, 44.85) while lowest pooled prevalence of AmpC producing E. coli 6.28% (95% CI: 2.99, 9.58) and K. pneumoniae 5.41% (95% CI: 1.73, 9.09) was observed among studies conducted before the year 2016.</p><p><strong>Conclusion: </strong>This study showed an increase in AmpC producing E. coli and K. pneumoniae in Africa over the past 20 years. Therefore, regular identification of AmpC, infection prevention control, strengthening of the antimicrobial resistance surveillance system and an effective antibiotic policy are required to combat the antibiotics resistance in Africa.</p><p><strong>Prospero registration identification number: </strong>CRD42024501640.</p>","PeriodicalId":7950,"journal":{"name":"Antimicrobial Resistance and Infection Control","volume":"14 1","pages":"109"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465745/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Resistance and Infection Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13756-025-01578-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The emergence of AmpC beta-lactamase (AmpC) poses a significant challenge in the context of antimicrobial resistance (AMR). AmpC confers resistance to narrow- and broad- spectrum cephalosporins, beta-lactam/beta-lactamase inhibitor combinations and aztreonam making it clinically relevant and presenting a formidable threat to effective therapeutic interventions. Thus, the aim of this study was to assess magnitude of AmpC producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) in Africa.

Methods: Articles were extensively searched in bibliographic databases and grey literature using entry terms and combinations key words. Electronic databases such as PubMed, Scopus, Science Direct, Embase, and other online sources such as African Journal Online, Google Scholar, and ResearchGate were used to find relevant articles. Furthermore, the Joanna Briggs Institute quality appraisal tool was used to assess the quality of the included studies. Studies meeting eligibility criteria were extracted in MS Excel and exported to STATA version 14 software for statistical analysis. A random-effects model was used to compute the pooled prevalence of AmpC producing E. coli and K. pneumoniae. Heterogeneity was quantified by using the Cochrane Q test and I2 statistics. Publication bias was assessed using a funnel plot and Egger's test. Additionally, sensitivity analysis was conducted to assess the impact of a single study on the pooled effect size.

Result: Of the 2,619 studies identified, 25 studies were eligible for quantitative analysis, involving a total of 11,908 E. coli, and 4,654 K. pneumoniae isolates. The overall pooled prevalence of AmpC producing E. coli and K. pneumoniae in Africa was 18.79% (95% CI: 15.00, 22.58). The pooled prevalence of AmpC producing E. coli and K. pneumoniae were 15.32% (95% CI: 12.03, 18.61) and 17.25% (95% CI: 13.18, 21.32), respectively. There was significant heterogeneity among studies (I2 = 99.0%, p < 0.001). Our study depicted that Egypt had the highest pooled prevalence of AmpC producing E. coli and K. pneumoniae with 28.91% (14.74, 43.08) and 27.84% (8.47, 47.21) respectively. Furthermore, studies conducted after 2020 showed the highest pooled prevalence of AmpC producing E. coli 28.29% (11.78, 44.80) and K. pneumoniae 29.04% (13.13, 44.85) while lowest pooled prevalence of AmpC producing E. coli 6.28% (95% CI: 2.99, 9.58) and K. pneumoniae 5.41% (95% CI: 1.73, 9.09) was observed among studies conducted before the year 2016.

Conclusion: This study showed an increase in AmpC producing E. coli and K. pneumoniae in Africa over the past 20 years. Therefore, regular identification of AmpC, infection prevention control, strengthening of the antimicrobial resistance surveillance system and an effective antibiotic policy are required to combat the antibiotics resistance in Africa.

Prospero registration identification number: CRD42024501640.

非洲产生AmpC β -内酰胺酶的大肠杆菌和肺炎克雷伯菌的患病率:一项系统综述和荟萃分析
背景:AmpC β -内酰胺酶(AmpC)的出现在抗菌药物耐药性(AMR)的背景下提出了重大挑战。AmpC对窄谱和广谱头孢菌素、β -内酰胺/ β -内酰胺酶抑制剂组合和氨曲南具有耐药性,使其具有临床意义,并对有效的治疗干预构成巨大威胁。因此,本研究的目的是评估非洲产生AmpC的大肠埃希菌(E. coli)和肺炎克雷伯菌(K. pneumoniae)的数量。方法:采用检索词和组合关键词对文献数据库和灰色文献进行广泛检索。电子数据库如PubMed、Scopus、Science Direct、Embase和其他在线资源如African Journal online、谷歌Scholar和ResearchGate被用来查找相关文章。此外,乔安娜布里格斯研究所的质量评估工具被用来评估纳入研究的质量。在MS Excel中提取符合入选标准的研究,导出到STATA version 14软件中进行统计分析。采用随机效应模型计算产生AmpC的大肠杆菌和肺炎克雷伯菌的总流行率。异质性采用Cochrane Q检验和I2统计量进行量化。采用漏斗图和Egger检验评估发表偏倚。此外,进行敏感性分析以评估单个研究对合并效应大小的影响。结果:在鉴定的2619项研究中,25项研究符合定量分析的条件,共涉及11,908株大肠杆菌和4,654株肺炎克雷伯菌。非洲产AmpC的大肠杆菌和肺炎克雷伯菌的总流行率为18.79% (95% CI: 15.00, 22.58)。产AmpC的大肠杆菌和肺炎克雷伯菌的总患病率分别为15.32% (95% CI: 12.03, 18.61)和17.25% (95% CI: 13.18, 21.32)。结论:本研究显示,在过去的20年中,非洲产生AmpC的大肠杆菌和肺炎克雷伯菌的数量有所增加。因此,需要定期查明AmpC、预防感染控制、加强抗菌素耐药性监测系统和制定有效的抗生素政策来防治非洲的抗生素耐药性。普洛斯彼罗注册识别号:CRD42024501640。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antimicrobial Resistance and Infection Control
Antimicrobial Resistance and Infection Control PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES
CiteScore
9.70
自引率
3.60%
发文量
140
审稿时长
13 weeks
期刊介绍: Antimicrobial Resistance and Infection Control is a global forum for all those working on the prevention, diagnostic and treatment of health-care associated infections and antimicrobial resistance development in all health-care settings. The journal covers a broad spectrum of preeminent practices and best available data to the top interventional and translational research, and innovative developments in the field of infection control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信